NEW ORLEANS — Patients with acute ischemic stroke (AIS) who have elevated factor VIII levels (in excess of 150%) may be at increased risk for recurrent thrombotic events, and these recurrent events ...

FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients ...

Please provide your email address to receive an email when new articles are posted on . A single infusion of verbrinacogene setparvovec resulted in normal factor IX levels among all 10 men who ...

An investigational, once-weekly prophylactic treatment provided "superior bleeding prevention" as well as normal or near-normal factor VIII activity in patients with severe hemophilia A, according to ...

Nine out of 10 patients with hemophilia B dosed with FLT180a were able to stop their weekly infusions of replacement factor IX. A single gene therapy injection in 10 patients with hemophilia B ...

Venous thromboembolism (VTE; deep venous thrombosis [DVT] and/or pulmonary embolism) is a major medical problem, which affects approximately 1 in 1000 persons per year. VTE is a multicausal disease ...